Download full announcement 

EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (“RenalytixAI”), that on 26 April 2019 EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

Christopher Mills, Julian Baines and Richard Evans (Chairman, CEO and FD/COO respectively of EKF) are each directors of, and directly and indirectly shareholders in, RenalytixAI.

Following the above transaction, which took place at an average price of 123.5973 pence per RenalytixAI share, EKF’s interest in RenalytixAI is now in 2,677,981 Ordinary Shares, representing 4.98% of RenalytixAI’s issued share capital.

Further details of the underlying trades are disclosed in the announcement by RenalytixAI in this regard.

Enquiries: